Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Skin Neoplasms 2Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Melanoma 1Kidney Neoplasms 1

Interventions

aldesleukin 16Cyclophosphamide 14fludarabine phosphate 11Interleukin-2 11fludarabine 10Nivolumab 7pembrolizumab 5cemiplimab 5Ipilimumab 5Temozolomide 4Fluorouracil 4Aminolevulinic Acid 4sonidegib 3Surgical Procedures, Operative 3Radiotherapy 3zanolimumab 2trametinib 2talabostat 2montanide ISA 51 2dabrafenib 2Whole-Body Irradiation 2Tablets 2Semaxinib 2Radiation 2Petrolatum 2Peptides 2MART-1 Antigen 2Gefitinib 2Eflornithine 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Skin Neoplasms × zanolimumab × Clear all
NCT00071071 2023-05-18

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
25 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00071084 2023-04-28

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
22 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡